Stage IV non-small cell lung cancer
Conditions
Interventions
Total:the concurrent three-dimensional radiotherapy of primary tumor and the concurrent or sequential radiotherapy of metastasis base on certain cycles chemotherapy.
Sponsors
The Affiliated Hospital of Guiyang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Untreated non-small cell lung cancer confirmed by pathology or cytology; 2. Stage IV according to UICC 2002 criteria; 3. Distant metastasis: suitable for radiotherapy. (the number of organs with metastasis foci =3, the metastasis foci on liver =1, the patient is sane with brain metastases, pulmonary metastasis does not affect lung function and the metastasis foci can be treated by radiotherapy, no irreversible serious events caused by bone metastasis affecting quality of life); 4. Informed consent signed before treatment (chemotherapy and concurrent three-dimensional radiotherapy treatment); 5. No contraindication of chemotherapy and radiotherapy; 6. The prescription dose =60Gy (V100=PTV), V20 of lung =32%; 7. Aged between 18 and 75 years old; ECOG 0 to 2 or KPS = 70; 8. Patients without important organ dysfunction; blood routine, liver, kidney and heart function is normal.(WBC =4.0G/L, NEUT=2.0G/L, PLT=100G/L, HGB=100g/L, FEV1>50%); 9. Patients with good compliance to treatment received and follow-up.
Exclusion criteria
Exclusion criteria: 1. Do not meet the inclusion criteria of pathology, stage and KPS; 2. The IV stage patients with uncontrolled malignant pleural effusion; 3. The patients with diffuse liver or lung metastasis which lead to liver or pulmonary dysfunction; 4. The patients with uncontrolled hypertension, uncontrolled diabetes, unstable angina, history of myocardial infarction, symptomatic congestive heart failure attacked in last one year; the patients with clinically diagnosed heart valve disease, bacterial, fungal or viral infections, mental disorders, severe pulmonary dysfunction; 5. The pregnant or breast-feeding patients 6. The patients with history of malignancy before inclusion (except for basal cell carcinoma, in situ cervical cancer, cured early prostate cancer); 7. The patients with allergic constitution or allergic to any research durg; 8. Patients with poor compliance; 9. The patients not suitable for inclusion evaluated by researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Local progression-free survival;Quality of Life; | — |
Secondary
| Measure | Time frame |
|---|---|
| Local control rat; | — |
Countries
China
Contacts
Public ContactBing Lu
Outcome results
None listed